目的 觀察阿托伐他汀聯(lián)合阿替普酶治療急性心肌梗死的治療效果。方法 選取2015年9月—2016年9月重慶市合川區(qū)中西醫(yī)結(jié)合醫(yī)院收治的急性心肌梗死患者86例，隨機(jī)分為對照組和治療組，每組各43例。對照組靜脈注射注射用阿替普酶，120 mg/d，180 min內(nèi)注射完畢。治療組在對照組治療基礎(chǔ)上口服阿托伐他汀鈣片，1片/次，2次/d。兩組患者均連續(xù)治療15 d。觀察兩組的臨床療效，同時(shí)比較兩組治療前后心率、心輸出量、左心室射血分?jǐn)?shù)的變化情況。觀察兩組病死率、休克發(fā)生率、再梗發(fā)生率及不良反應(yīng)發(fā)生率。結(jié)果 治療后，對照組和治療組的總有效率分別為74.42%、95.35%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療后，兩組患者的心率明顯降低，心輸出量、左心室射血分?jǐn)?shù)明顯升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；治療后，治療組患者的心率低于對照組，心輸出量和左心室射血分?jǐn)?shù)高于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。治療組患者病死率、休克發(fā)生率、再梗發(fā)生率、不良反應(yīng)發(fā)生率均明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 阿托伐他汀聯(lián)合阿替普酶治療急性心肌梗死具有較好的臨床療效，可明顯改善患者的心功能相關(guān)指標(biāo)，同時(shí)可改善患者預(yù)后，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the curative effect of atorvastatin combined with alteplase in treatment of acute myocardial infarction. Methods Patients (86 cases) with acute myocardial infarction in Hechuan District Hospitals of Traditional Chinese and Western Medicine in Chongqing from September 2015 to September 2016 were randomly divided into control (43 cases) and treatment (43 cases) groups. Patients in the control group were iv administered with Alteplase for injection in 180 min, 120 mg/d. Patients in the treatment group were po administered with Atorvastatin Calcium Tablets on the basis of the control group, 1 tablet/time, twice daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacy was evaluated, and the changes of heart rate, cardiac output, and left ventricular ejection fraction in two groups before and after treatment were compared. The fatality rate, shock incidence, reterrier incidence, and adverse reactions incidence were observed. Results After treatment, the clinical efficacy in the control and treatment groups were 74.42% and 95.35%, respectively, and there was difference between two groups (P < 0.05). After treatment, the heart rate in two groups significantly decreased, but cardiac output and left ventricular ejection fraction obviously increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the heart rate in the treatment group was lower than that in the control group, and cardiac output and left ventricular ejection fraction were higher than those in the control group, and there was difference between two groups (P < 0.05). The fatality rate, shock incidence, reterrier incidence, and adverse reactions incidence were significantly lower than those in the control group, and there was difference between two groups (P < 0.05). Conclusion Atorvastatin combined with alteplase has good clinical effect in treatment of acute myocardial infarction, and can obviously improve the cardiac function related indicators and can improve the prognosis of patients, which has a certain clinical application value.